HR. 1532In Committee
Scientific EXPERT Act of 2025
Requires the FDA to take part in recurring externally led scientific meetings on rare disease drug development and report how that input informed approvals
Plain-English overview
What this bill does
Requires the FDA to take part in recurring externally led scientific meetings on rare disease drug development and report how that input informed approvals
Key points
- Establish Reagan Udall steering committee
- Require FDA participation in meetings
- Require approval input disclosures
- Direct meeting summaries and next steps
Current status
Where it stands
Status
In Committee
Latest action
2025-02-24 — Referred to the House Committee on Energy and Commerce.
Related context
Topics and policy areas
undefinedAdvisory bodiesCongressional oversightDrug safety, medical device, and laboratory regulationGovernment information and archivesHealthMedical researchResearch administration and funding